SOST and AL amyloidosis: Eda et al. investigated sources of sclerostin and efficiencies of treatments with anti-sclerostin antibodies with a proteasome inhibitor Carfilzomib approved for the treatment of multiple myeloma using humanized multiple myeloma xenograft model mice [92].